Voyager Therapeutics, Inc.

Voyager Therapeutics is a clinical-stage biotechnology company dedicated to leveraging the power of human genetics to modify the course of—and ultimately cure—neurological diseases. The company utilizes its proprietary TRACER™ AAV capsid discovery platform to generate novel capsids that demonstrate exceptional delivery across the blood-brain barrier, enabling the development of targeted, durable gene therapies. Voyager's pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's ataxia, and other central nervous system (CNS) conditions. The company operates through a mix of wholly-owned programs and strategic collaborations with major pharmaceutical and biotechnology partners.